However, studies support GLP-1RA to be cost effective in comparison to insulin therapy as per the healthcare models in high income countries while the parameter for comparison between the two include the increased risk of hypoglycaemia and all-cause mortality alongside emergency room visits and hospitalization. The gene discussed is INS; the disease is Hypoglycemia.